Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

2020953 citationsJournal Articlebronze Open Access

Authors

Sotirios Tsimikas · Ionis Pharmaceuticals (United States)

Ewa Karwatowska‐Prokopczuk · Montreal Heart Institute

Ioanna Gouni‐Berthold · University of Cologne

Jean‐Claude Tardif · Montreal Heart Institute

Seth J. Baum · Montreal Heart Institute

Elizabeth Steinhagen-Thiessen · Universitätsmedizin Greifswald

Michael D. Shapiro

Abstract

APO(a)-L<sub>Rx</sub> reduced lipoprotein(a) levels in a dose-dependent manner in patients who had elevated lipoprotein(a) levels and established cardiovascular disease. (Funded by Akcea Therapeutics; ClinicalTrials.gov number, NCT03070782.).

Topics & Keywords

Lipoproteins and Cardiovascular Health Diabetes, Cardiovascular Risks, and Lipoproteins Health Systems, Economic Evaluations, Quality of Life

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 382, Issue 3, pp. 244-255

DOI: 10.1056/nejmoa1905239

Field-Weighted Citation Impact: 114.10